Abiopharma

Massacesi Cristian 🔴 sold 6.2K shares of BRISTOL MYERS SQUIBB CO (BMY) at $64.57 Transaction Date: Sep 09, 2026 | Filing ID: 000006

📋 Massacesi Cristian (Officer) plans to sell 6K shares of BRISTOL MYERS SQUIBB CO (at $64.57 each, total $403K) Filed: Sep 09, 2026 | ID: 006809

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

📋 Holzer Phil M (Officer) plans to sell 500 shares of BRISTOL MYERS SQUIBB CO (at $67.50 each, total $34K) Filed: Aug 25, 2026 | ID: 006424

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibbs First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

New Form SCHEDULE 13G - BRISTOL MYERS SQUIBB CO <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000422 <b>Size:</b> 8 KB

(10% Negative) BRISTOL MYERS SQUIBB CO (BMY) Reports Q3 2026 Financial Results

Director YALE PHYLLIS R 🟢 acquired 607 shares (1 derivative) of BRISTOL MYERS SQUIBB CO (BMY) Transaction Date: Jun 30, 2026 | Filing ID: 000009

Director Samuels Theodore R. II 🟢 acquired 889 shares (1 derivative) of BRISTOL MYERS SQUIBB CO (BMY) Transaction Date: Jun 30, 2026 | Filing ID: 000008